Pfizer (PFE) Invested Capital (2009 - 2026)

Pfizer (PFE) has reported Invested Capital for 18 consecutive years, with $148.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 1.41% year-over-year to $148.7 billion in Q2 2026; TTM through Jun 2026 was $148.7 billion, a 1.41% decrease from a year earlier, with the FY2025 full-year figure at $151.6 billion, down 0.84% from the prior year.
• Invested Capital was $148.7 billion for Q2 2026 at Pfizer, down from $154.9 billion in the prior quarter.
• Over five years, Invested Capital peaked at $164.6 billion in Q3 2023 and troughed at $119.0 billion in Q2 2022.
• A 5-year average of $149.3 billion and a median of $152.8 billion in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital advanced 28.87% in 2023 and retreated 5.77% in 2025, its largest moves.
• Over 5 years, Invested Capital stood at $131.9 billion in 2022, then advanced by 22.58% to $161.6 billion in 2023, then retreated by 5.44% to $152.8 billion in 2024, then dropped by 0.84% to $151.6 billion in 2025, then retreated by 1.9% to $148.7 billion in 2026.
• The last three Invested Capital figures came in at $148.7 billion (Q2 2026), $154.9 billion (Q1 2026), and $151.6 billion (Q4 2025), per Business Quant data.